Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Key Highlights
- ➤Monte Rosa management to join four investor conference fireside chats November 9–December 1
- ➤Three clinical programs span autoimmune, inflammatory, and oncology diseases
- ➤QuEEN discovery engine combines AI-guided chemistry, structural biology, and proteomics
- ➤Monte Rosa maintains pharmaceutical collaborations in immunology, oncology, and neurology
BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: * Guggenheim's 3rd Annual Healthcare Innovation Conference (Boston, MA) – fireside chat, November 9, 2026, at 8:00 a.m. ET * UBS Global Biopharma Conference 2026 (London, UK) – fireside chat, November 16, 2026, at 12:00 p.m. GMT * Jefferies Global Healthcare Conference in London – fireside chat, November 17, 2026, at 10:00 a.m. GMT * Piper Sandler 38th Annual Healthcare Conference (New York, NY) – fireside chat, December 1, 2026, at 3:30 p.m. ET Webcasts of the fireside chats will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com, and archived versions will be made available for 30 days following the presentations.
Get started
Create a free account to read the full story.